Prognostic factors for survival and ambulatory status at 8 weeks with metastatic spinal cord compression in the SCORAD randomised trial
AuthorsHoskin, P. J.
Lester, J. F.
Thomas, S. S.
AffiliationMount Vernon Cancer Centre Northwood and University of Manchester, United Kingdom
MetadataShow full item record
AbstractBackground: Metastatic spinal cord compression (MSCC) carries a poor prognosis and management is based on the likelihood of maintaining mobility and predicted survival. Patients and method: SCORAD is a randomised trial of 686 patients comparing a single dose of 8 Gy radiotherapy with 20 Gy in 5 fractions. Data was split into a training set (412, 60%) and a validation set (274, 40%). A multivariable Cox regression for overall survival (OS) and a logistic regression for ambulatory status at 8 weeks were performed in the training set using baseline factors and a backward selection regression to identify a parsimonious model with p ≤ 0.10. Receiver Operating Characteristic (ROC) analysis evaluated model prognostic performance in the validation set. Validation of the final survival model was performed in a separate registry dataset (n = 348). Results: The survival Cox model identified male gender, lung, gastrointestinal, and other types of cancer, compression at C1-T12, presence of non-skeletal metastases and poor ambulatory status all significantly associated with worse OS (all p < 0.05). The ROC AUC for the selected model was 75% (95%CI: 69-81) in the SCORAD validation set and 68% (95%CI: 62-74) in the external validation registry data. The logistic model for ambulatory outcome identified primary tumour breast or prostate, ambulatory status grade 1 or 2, bladder function normal and prior chemotherapy all significantly associated with increased odds of ambulation at 8 weeks (all p < 0.05). The ROC AUC for the selected model was 72.3% (95% CI 62.6-82.0) in the validation set. Conclusions: Primary breast or prostate cancer, and good ambulatory status at presentation, are favourable prognostic factors for both survival and ambulation after treatment.
CitationHoskin PJ, Hopkins K, Misra V, Holt T, McMenemin R, McKinna F, et al. Prognostic factors for survival and ambulatory status at 8 weeks with metastatic spinal cord compression in the SCORAD randomised trial. Vol. 173, Radiotherapy and Oncology. Elsevier BV; 2022. p. 77–83.
JournalRadiotherapy and Oncology
- Effect of Single-Fraction vs Multifraction Radiotherapy on Ambulatory Status Among Patients With Spinal Canal Compression From Metastatic Cancer: The SCORAD Randomized Clinical Trial.
- Authors: Hoskin PJ, Hopkins K, Misra V, Holt T, McMenemin R, Dubois D, McKinna F, Foran B, Madhavan K, MacGregor C, Bates A, O'Rourke N, Lester JF, Sevitt T, Roos D, Dixit S, Brown G, Arnott S, Thomas SS, Forsyth S, Beare S, Reczko K, Hackshaw A, Lopes A
- Issue date: 2019 Dec 3
- Surgical results of metastatic spinal cord compression (MSCC) from non-small cell lung cancer (NSCLC): analysis of functional outcome, survival time, and complication.
- Authors: Park SJ, Lee CS, Chung SS
- Issue date: 2016 Mar
- Prognostic factors in a series of 504 breast cancer patients with metastatic spinal cord compression.
- Authors: Rades D, Douglas S, Veninga T, Stalpers LJ, Bajrovic A, Rudat V, Schild SE
- Issue date: 2012 Apr
- Interventions for the treatment of metastatic extradural spinal cord compression in adults.
- Authors: George R, Jeba J, Ramkumar G, Chacko AG, Tharyan P
- Issue date: 2015 Sep 4
- Escalation of radiation dose beyond 30 Gy in 10 fractions for metastatic spinal cord compression.
- Authors: Rades D, Karstens JH, Hoskin PJ, Rudat V, Veninga T, Schild SE, Dunst J
- Issue date: 2007 Feb 1